Citation Impact
Citing Papers
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
2016
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
2015
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
2012
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
2011
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
2008
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
2008
Targeting HER proteins in cancer therapy and the role of the non-target HER3
2007
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
2005
Diagnostic and prognostic significance of clonal T‐cell receptor beta gene rearrangements in lymph nodes of patients with mycosis fungoides
1993
EGFR Antagonists in Cancer Treatment
2008 Standout
Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome
1997
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
A view on drug resistance in cancer
2019 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Comparing antibody and small-molecule therapies for cancer
2006
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
2016
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
2008
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
2006
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Treating ALK-positive lung cancer—early successes and future challenges
2012
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
2011
ErbBs in lung cancer
2008
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
2009
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Histopathologic Staging at Initial Diagnosis of Mycosis Fungoides and the Sézary Syndrome
1988
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
2006
Emerging Biological Principles of Metastasis
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
2005
Where next for gefitinib in patients with lung cancer?
2006
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
2003
Leu-8/CD7 antigen expression by CD3+ T cells: Comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values
1990
Selective Inhibitors of Glutathione Transferase P1 with Trioxane Structure as Anticancer Agents
2015
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
2007
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
2008
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Acquired resistance to TKIs in solid tumours: learning from lung cancer
2014
Metastatic colonization by circulating tumour cells
2016 StandoutNature
The Sézary syndrome: hematologic criteria
2003
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
The current status of targeted therapy for non‐small cell lung cancer
2009
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome
1993
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
2016
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
2009
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
2007
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
2007
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
2002
Modeling oncogene addiction using RNA interference
2008
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
2006
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
2001
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2005
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
2007
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
2005
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
2006
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
2006
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
2007
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
2005
Metabolic reprogramming and cancer progression
2020 StandoutScience
Fine-Needle Aspiration Biopsy in the Evaluation of Lymphadenopathy Associated With Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sézary Syndrome)
2000
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
2008
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma
2001
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
2005
Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides
2001
Histologic assessment of lymph nodes in mycosis fungoides/sézary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system
1985
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
2011
Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells BearingEGFRGene Mutation and Amplification
2007
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
2007
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Demonstration of Frequent Occurrence of Clonal T Cells in the Peripheral Blood of Patients With Primary Cutaneous T-Cell Lymphoma
1997
Clinical Staging for Cutaneous T-Cell Lymphoma
1984
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
2010
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
2007 Standout
Works of Mark S. Huberman being referenced
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
2006
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
2015
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
2010
BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
2007
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice
2013
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
2006
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
2014
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
2015
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
2016
Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
2009
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
2004
Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer
1985
Hepatic involvement in the cutaneous T-cell lymphomas. Results of percutaneous biopsy and peritoneoscopy
1980
A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression.
2015
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
2008
A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors
2000
Prospective Staging Evaluation of Patients with Cutaneous T-Cell Lymphomas
1980